Stada's 2006 income up 78% to 92M euros

12 March 2007

German generic drugmaker Stada Arzneimittel says that, for the full year 2006, its net income increased 78% to 91.8 million euros ($120.4 million). The company attributed the surge in profits to a 22% hike in its revenues, which were 1.25 billion euros for the year.

Stada added that the expansion, which was the 11th consecutive period of turnover growth, was driven by the success of its operations outside Germany, which contributed 763.2 million euros, representing 61.3% of its annual revenue. The company also said that it had achieved a 14.5% increase in its operating profit margin during 2006,which was in line with a previously stated goal.

Outlook for 2007

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight